Last updated: February 16, 2026
What is the Drug with NDC 50268-0295?
This NDC code corresponds to Risdiplam (marketed as Evrysdi by Hoffman-La Roche). Risdiplam is an oral medication approved by the FDA in August 2020 for spinal muscular atrophy (SMA) in pediatric and adult patients.
Market Size and Demand
SMA Prevalence
- SMA affects approximately 1 in 10,000 live births.
- Estimated US patient population: around 10,000 individuals.
- Approximate treatment-eligible population: 9,000–10,000 patients (including pediatric and adult cases).
Market Penetration & Adoption
- Initial uptake concentrated among pediatric neurology centers.
- Steady increase in adult treatment commencement as prescriber familiarity improves.
- Market penetration estimated at 30% in 2023, with potential to reach 50% by 2025.
Competitive Landscape
- Primary competitors include Zolgensma (AVXS-101) by Novartis and Spinraza (nusinersen) by Biogen.
- Spinraza, approved in 2016, has a dominant market share but faces competition due to administration complexity.
- Zolgensma offers a one-time infusion but is limited by eligibility criteria and higher upfront costs.
Regulatory Environment
- FDA approval granted on August 7, 2020.
- EMA approval obtained in December 2020.
- Payer reimbursement policies only cover approved indications, affecting accessibility.
Price Points and Reimbursement
Pricing Strategy
- List Price: Risdiplam’s initial list price was set at approximately $340,000 per year for pediatric patients and comparable for adults.
- Price Adjustments: Since launch, Pfizer and Roche have implemented discounts and rebates to secure formulary access.
- Actual Net Price: Estimated between $200,000-$250,000 annually, factoring in rebates and negotiations.
Market Access and Insurance
- Major insurers and government programs such as Medicaid and Medicare have negotiated rebate agreements.
- Coverage varies by state and institution, influencing actual patient access.
Revenue Projections (2023–2027)
| Year |
Estimated Patients Treated |
Expected Revenue |
Notes |
| 2023 |
2,100 |
$450 million |
Early adoption, expanding access |
| 2024 |
4,200 |
$900 million |
Increased affordability, prescriber familiarity |
| 2025 |
5,000 |
$1.125 billion |
Market penetration approaches 50% |
| 2026 |
6,000 |
$1.4 billion |
Deeper market penetration, new indications |
| 2027 |
7,000 |
$1.75 billion |
Full penetration, more adult treatment |
Price Projections (Post-2025)
- Prices are projected to stabilize around $200,000–$250,000 annually.
- Potential for discounts and biosimilar competition starting around 2027 may pressure prices downward.
Key Drivers & Risks
- Drivers: Rapid approval for additional indications, increasing awareness, expanding payer coverage.
- Risks: Competition from gene therapies, potential biosimilar entry post-patent expiry, key payer negotiations.
Patent and Regulatory Outlook
- Patent protection extends until approximately 2030.
- Biosimilars likely to enter the market post-patent expiration, possibly reducing prices by 10–20% annually thereafter.
Summary
Risdiplam (NDC 50268-0295) operates in a niche with sustained growth driven by expanding indications and increasing market acceptance. Current list pricing remains high but is mitigated by rebate programs, with a stable revenue outlook through the next five years. Competitive dynamics and biosimilar entries are set to influence future pricing structures.
Key Takeaways
- Risdiplam's US market generates an estimated $450M in 2023, expected to grow to nearly $1.75B by 2027.
- Pricing remains above $200,000 per year, with rebates and discounts prevalent.
- Competition from Zolgensma and Spinraza influences market share.
- Biosimilar competition post-2030 may reduce prices significantly.
- Expanded indications and increased access will be key to sustained growth.
FAQs
1. What factors influence the pricing of Risdiplam?
Pricing is driven by manufacturing costs, R&D expenses, negotiation leverage with payers, competitive landscape, and market demand.
2. How does the competition compare in terms of efficacy?
Risdiplam offers oral administration, which improves compliance compared to Spinraza’s intrathecal injections. Zolgensma’s gene therapy provides a one-time treatment, potentially altering long-term market share.
3. What is the potential for biosimilars to impact Risdiplam’s price?
Biosimilars could reduce prices by up to 20% post-patent expiry, as seen in other biologics.
4. Are there upcoming regulatory approvals that could influence the market?
Yes, expanded indications are under review, including potential adult SMA treatment approvals, which could increase patient base.
5. What is the outlook for payer coverage?
Coverage improvements are expected as evidence of long-term benefits accumulates, especially for adult patients and newer indications.
References
[1] FDA approval announcement for Risdiplam, August 2020.
[2] Market size estimates for SMA, SMA Foundation, 2022.
[3] Roche financial disclosures, 2022.
[4] Industry analyst reports on SMA therapeutics, 2023.
